Shopping Cart
- Remove All
- Your shopping cart is currently empty
BTB01303 is a glutamate release inhibitor that targets the high levels of glutamate released by cancer cells, which disrupts normal bone turnover and can lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | BTB01303 is a glutamate release inhibitor that targets the high levels of glutamate released by cancer cells, which disrupts normal bone turnover and can lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain [1]. |
In vitro | BTB01303 inhibits breast cancer cells from releasing high levels of glutamate, alleviating bone pain caused by glutamate-induced disruption of normal bone turnover [1]. |
Molecular Weight | 324.16 |
Formula | C15H11Cl2NO3 |
Cas No. | 652129-89-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.